Biotech Values

[poorgradstudent]

Re: CNAT

Wouldn't those safety issues be visible as they dosed aprox 500 patients overall and conducted phase 1 studies?

I think AEs are always a bit of a wild card. Perhaps the short duration of treatment with the drug works in its favour. Nonetheless I think it's worthwhile being on guard until safety data comes in from a larger number of patients are treated at the therapeutic dose.